- 期刊
- OpenAccess
Ultra-short Acting Insulin
摘要
Background. The goal of prandial insulin therapy is to provide optimal control of postprandial glucose excursions. However, current insulin are absorbed too slowly and do not replicate the physiological insulin secretion profile in healthy individuals. Ultra-short acting insulin is being developed with a view to further improving on these pharmacokinetic/pharmacodynamic properties. Findings. Several attempts have been made to develop ultra-short acting insulins. Many of them have focused on conjugation with excipients that accelerate absorption of insulin monomers. These include recombinant insulin containing ethylenediaminetetraacetic acid and citrate (VIAject), insulin with recombinant hyaluronidase (rHuPH20), faster-acting insulin aspart, and BioChaperone Lispro. Ultra-short acting insulins have faster onset of appearance and higher early exposure, which results in a greater early glucose-lowering effect in subjects with diabetes as compared with rapid-acting insulin analogues and human insulin. Conclusion. Ultra-short acting insulins offer better opportunities for diabetes to improve postprandial glucose control, reduce risk of hypoglycemia, and provide more flexibility. The long-term efficacy and safety of ultra-short acting insulins need to be demonstrated in large clinical trials.